BlackRock
ALXN

BlackRock’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-17,495,607
Closed -$3.21B – 5781
2021
Q2 		$3.21B Sell
17,495,607
-54,688
-0.3% -$9.39M 0.09% 199
2021
Q1 		$2.68B Sell
17,550,295
-617,981
-3% -$95.6M 0.08% 238
2020
Q4 		$2.84B Buy
18,168,276
+68,531
+0.4% +$8.81M 0.09% 202
2020
Q3 		$2.07B Sell
18,099,745
-428,185
-2% -$46.2M 0.08% 242
2020
Q2 		$2.08B Buy
18,527,930
+2,016,954
+12% +$214M 0.08% 219
2020
Q1 		$1.48B Buy
16,510,976
+597,605
+4% +$58.7M 0.07% 251
2019
Q4 		$1.72B Sell
15,913,371
-45,163
-0.3% -$4.83M 0.07% 283
2019
Q3 		$1.56B Sell
15,958,534
-267,081
-2% -$30.1M 0.07% 285
2019
Q2 		$2.13B Buy
16,225,615
+199,298
+1% +$25.7M 0.09% 215
2019
Q1 		$2.17B Sell
16,026,317
-205,043
-1% -$25.5M 0.1% 203
2018
Q4 		$1.58B Sell
16,231,360
-71,168
-0.4% -$8.41M 0.08% 239
2018
Q3 		$2.27B Buy
16,302,528
+41,943
+0.3% +$5.26M 0.1% 199
2018
Q2 		$2.02B Sell
16,260,585
-1,615,817
-9% -$189M 0.09% 212
2018
Q1 		$1.99B Sell
17,876,402
-128,208
-0.7% -$15.3M 0.1% 208
2017
Q4 		$2.15B Sell
18,004,610
-1,352,721
-7% -$165M 0.1% 196
2017
Q3 		$2.72B Sell
19,357,331
-568,934
-3% -$77.3M 0.14% 146
2017
Q2 		$2.42B Buy
19,926,265
+1,298,185
+7% +$151M 0.13% 158
2017
Q1 		$2.26B Buy
18,628,080
+17,960,356
+2,690% +$2.32B 0.12% 161
2016
Q4 		$81.7M Buy
667,724
+18,442
+3% +$2.26M 0.12% 202
2016
Q3 		$79.6M Buy
649,282
+147,923
+30% +$19M 0.11% 200
2016
Q2 		$58.5M Buy
501,359
+5,671
+1% +$805K 0.09% 256
2016
Q1 		$69M Sell
495,688
-202,372
-29% -$29.7M 0.11% 206
2015
Q4 		$133M Sell
698,060
-20,669
-3% -$3.61M 0.2% 114
2015
Q3 		$112M Buy
718,729
+14,749
+2% +$2.69M 0.18% 128
2015
Q2 		$127M Buy
703,980
+44,775
+7% +$7.73M 0.19% 117
2015
Q1 		$114M Buy
659,205
+9,530
+1% +$1.72M 0.16% 146
2014
Q4 		$120M Buy
649,675
+22,828
+4% +$4.23M 0.17% 131
2014
Q3 		$104M Sell
626,847
-14,013
-2% -$2.3M 0.15% 151
2014
Q2 		$100M Sell
640,860
-37,072
-5% -$5.85M 0.15% 150
2014
Q1 		$103M Buy
677,932
+126,943
+23% +$20.2M 0.17% 134
2013
Q4 		$73.2M Buy
550,989
+149,643
+37% +$18M 0.12% 188
2013
Q3 		$46.6M Sell
401,346
-25,112
-6% -$2.76M 0.09% 250
2013
Q2 		$39.3M Buy
+426,458
New +$41.1M 0.08% 266

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

BlackRock's ALXN Position: Q3 2021 in Review

BlackRock sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 17,495,607 shares — an estimated $3.21B sold.

BlackRock first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $3.21B in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • BlackRock reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • BlackRock sold 17,495,607 Alexion Pharmaceuticals shares in Q3 2021, an estimated $3.21B.
  • BlackRock first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • BlackRock's Alexion Pharmaceuticals position peaked at $3.21B in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on BlackRock's 13F filing for Q3 2021, filed 9 Nov 2021.